Rockwell Medical Announces Growth Plan and New Therapeutic Opportunities for Its Ferric Pyrophosphate Citrate (FPC) Platform
The MarketWatch News Department was not involved in the creation of this content.
WIXOM, Mich., Sep 24, 2020 (GLOBE NEWSWIRE via COMTEX) —
-New indications for FPC platform provide significant growth opportunity-
-Anticipates Type C meeting with FDA for home infusion in Q1 2021and for acute heart failure in 2H 2021–
-Well capitalized to fund dialysis business and advance clinical development for home infusion indication-
-Archived webcast available on corporate website–
WIXOM, Mich., Sept. 24, 2020 (GLOBE NEWSWIRE) — Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and iron deficiency anemia management and improving outcomes for patients around the world, earlier today concluded its Management and Key Opinion Leader (KOL) conference call and webcast to discuss potential novel indications for its ferric pyrophosphate citrate (FPC) platform. The conference call included presentations